Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Suntory Oceania’s $3bn beverage business launched in Qld

Heat and Control showcases sustainable food processing solutions

Top 5 keys to successful refrigerated transport in the last mile

Haigh's CEO announces retirement

Nestlé and IBM partner to identify novel packaging materials

Deepfakes mimicking health professionals pose real risk

Diagnostic reference levels for mammography now a step closer

Renewal fee rebate for parental and other leave now in effect

SA reaches state-first allied health enterprise agreement

WA's Health Support Services appoints Giles Nunis CEO

Sparc Hydrogen receives $2.75m commercialisation grant

Green approach to increase wastewater recycling in regional towns

US company to receive $4.9m from ARENA for solar installation robot trial

ANSTO technology removes key radioactive contaminant in critical minerals

Global manufacturing PMI up, Australia down slightly

Lonza bone marrow and cord blood mononuclear cells

Cayman Chemical Bio-Active Lipid I Screening Library (96-Well)

Echelon Biosciences ionisable lipids

BioStatus CyTRAK Orange fluorescent dye

Content from other channels on our network